JP2012140432A5 - - Google Patents

Download PDF

Info

Publication number
JP2012140432A5
JP2012140432A5 JP2012015294A JP2012015294A JP2012140432A5 JP 2012140432 A5 JP2012140432 A5 JP 2012140432A5 JP 2012015294 A JP2012015294 A JP 2012015294A JP 2012015294 A JP2012015294 A JP 2012015294A JP 2012140432 A5 JP2012140432 A5 JP 2012140432A5
Authority
JP
Japan
Prior art keywords
heterocyclyl
cycloalkyl
alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012015294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012140432A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012140432A publication Critical patent/JP2012140432A/ja
Publication of JP2012140432A5 publication Critical patent/JP2012140432A5/ja
Pending legal-status Critical Current

Links

JP2012015294A 1999-12-15 2012-01-27 抗菌剤としてのダプトマイシンアナログ Pending JP2012140432A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17094399P 1999-12-15 1999-12-15
US60/170,943 1999-12-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001544761A Division JP4990456B2 (ja) 1999-12-15 2000-12-15 抗菌剤としてのダプトマイシンアナログ

Publications (2)

Publication Number Publication Date
JP2012140432A JP2012140432A (ja) 2012-07-26
JP2012140432A5 true JP2012140432A5 (US20040106767A1-20040603-C00005.png) 2013-04-11

Family

ID=22621910

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001544761A Expired - Fee Related JP4990456B2 (ja) 1999-12-15 2000-12-15 抗菌剤としてのダプトマイシンアナログ
JP2012015294A Pending JP2012140432A (ja) 1999-12-15 2012-01-27 抗菌剤としてのダプトマイシンアナログ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001544761A Expired - Fee Related JP4990456B2 (ja) 1999-12-15 2000-12-15 抗菌剤としてのダプトマイシンアナログ

Country Status (13)

Country Link
US (2) US6911525B2 (US20040106767A1-20040603-C00005.png)
EP (4) EP1240181A2 (US20040106767A1-20040603-C00005.png)
JP (2) JP4990456B2 (US20040106767A1-20040603-C00005.png)
KR (1) KR20020063227A (US20040106767A1-20040603-C00005.png)
CN (1) CN1425025A (US20040106767A1-20040603-C00005.png)
AU (1) AU784755B2 (US20040106767A1-20040603-C00005.png)
BR (1) BR0017026A (US20040106767A1-20040603-C00005.png)
CA (1) CA2393907A1 (US20040106767A1-20040603-C00005.png)
IL (2) IL150223A0 (US20040106767A1-20040603-C00005.png)
MX (1) MXPA02006029A (US20040106767A1-20040603-C00005.png)
NO (1) NO20022888L (US20040106767A1-20040603-C00005.png)
WO (1) WO2001044272A2 (US20040106767A1-20040603-C00005.png)
ZA (1) ZA200205106B (US20040106767A1-20040603-C00005.png)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0016467A (pt) * 1999-12-15 2002-08-27 Cubist Pharm Inc Lipopeptìdeos como agentes antibacterianos
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
NZ571597A (en) 2000-12-18 2010-05-28 Cubist Pharm Inc Method for preparing crystalline and crystal-like forms of purified daptomycin lipopeptides
DE60232158D1 (de) * 2001-08-06 2009-06-10 Cubist Pharm Inc Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
CA2458644A1 (en) * 2001-08-28 2003-03-13 Pharmacia Corporation Crystaline clindamycin free base
US6767718B2 (en) 2002-05-10 2004-07-27 Biosource Pharm, Inc. Lipodepsipeptide antibiotics and methods of preparation
AU2003265241A1 (en) * 2002-05-23 2003-12-12 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
AU2003240545A1 (en) 2002-06-06 2003-12-22 Therapeutics Corporation Genome Use of ramoplanin to treat diseases associated with the use of antibiotics
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
ITMI20022076A1 (it) * 2002-10-01 2004-04-02 Antibioticos Spa Sali di intermedi del cefdinir.
US20040132764A1 (en) * 2002-10-23 2004-07-08 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Antibiotics for the treatment of infections in acidic environments
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CA2587848A1 (en) * 2004-11-12 2006-10-19 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
AU2006242535B2 (en) * 2005-04-29 2012-08-09 Merck Sharp & Dohme Corp. Therapeutic compositions
WO2007127218A2 (en) * 2006-04-26 2007-11-08 Taro Pharmaceuticals U.S.A., Inc. Streptomyces-derived antimicrobial compound and method of using same against antibiotic-resistant bacteria
CA2659684A1 (en) * 2006-08-02 2008-02-07 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
US8662086B2 (en) 2007-02-06 2014-03-04 BBK Tobacco & Foods, LLP Reclosable package with magnetic clasp for rolling papers used in smoking articles
US20080185010A1 (en) * 2007-02-06 2008-08-07 Kesselman Joshua D Interleaved Transparent Cellulose Paper with Opaque Adhesive
US8584854B2 (en) * 2007-02-06 2013-11-19 BBK Tobacco & Foods, LLP Reclosable package with magnetic clasp and detachable tray for rolling papers used in smoking articles
US20090020443A1 (en) * 2007-05-09 2009-01-22 Kesselman Joshua D Credit Card Carrying Pack for Rolling Papers
US9072319B2 (en) 2007-06-15 2015-07-07 Joshua D. Kesselman Rolling paper structures for creating smoking articles and gummed, coiled inserts for same
US9161572B2 (en) * 2007-06-15 2015-10-20 Bbk Tobacco & Foods, Inc. Structures for creating smoking articles and methods of packaging same
US20090014342A1 (en) * 2007-07-14 2009-01-15 Kesselman Joshua D Rolling papers and methods of packaging same
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CA2710602A1 (en) * 2007-12-26 2009-07-09 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
US8393332B2 (en) 2008-08-21 2013-03-12 BBK Tobacco & Foods, LLP Packaging for rolling papers for smoking articles
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
PL2379580T3 (pl) * 2008-12-22 2014-05-30 Merck Sharp & Dohme Nowe środki przeciwbakteryjne do leczenia zakażeń wywołanych bakteriami Gram-dodatnimi
NZ593892A (en) 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
ES2374779B1 (es) * 2010-03-10 2012-12-27 Universidad De Barcelona Compuestos péptidicos útiles como agentes antibacterianos.
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012011917A1 (en) * 2010-07-23 2012-01-26 Activbiotics Pharma, Llc Administration of rifalazil to immunocompromised patients
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
CN110577581A (zh) * 2018-06-07 2019-12-17 美国蓝博药业公司 一种新型的抑菌脂肽化合物、制备方法及其应用
CN109182563B (zh) * 2018-08-01 2020-07-14 浙江大学 检测20种dfrA类甲氧苄胺嘧啶类药物耐药基因的方法及所用试剂盒
CN113061164B (zh) * 2021-03-29 2023-01-10 四川大学 环脂肽类化合物及其在抗类风湿关节炎药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
DE3376424D1 (en) 1982-02-27 1988-06-01 Beecham Group Plc Antibacterial 1-normon-2-yl-heterocyclic compounds
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4396543A (en) 1982-05-21 1983-08-02 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
IL68700A0 (en) * 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
EP0178152B1 (en) 1984-10-09 1991-09-25 Eli Lilly And Company Production of a-21978c derivatives
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
ES2089133T3 (es) 1990-06-07 1996-10-01 Lilly Co Eli Desacilasa de lipopeptidos.
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
EP0712405A1 (en) 1993-08-13 1996-05-22 Smithkline Beecham Plc Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE544851T1 (de) 1996-03-08 2012-02-15 Astellas Pharma Inc Verfahren zur deacylierung von zyklischen lipopeptiden
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Similar Documents

Publication Publication Date Title
JP2012140432A5 (US20040106767A1-20040603-C00005.png)
JP2016525075A5 (US20040106767A1-20040603-C00005.png)
JP2015537008A5 (US20040106767A1-20040603-C00005.png)
JP2012092103A5 (US20040106767A1-20040603-C00005.png)
JP2015527333A5 (US20040106767A1-20040603-C00005.png)
JP2017526674A5 (US20040106767A1-20040603-C00005.png)
HRP20220899T1 (hr) Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba
JP2018516904A5 (US20040106767A1-20040603-C00005.png)
JP2016534037A5 (US20040106767A1-20040603-C00005.png)
EA201390884A1 (ru) Азабензимидазолы в качестве противовирусных средств в отношении респираторного синцитиального вируса
JP2014526533A5 (US20040106767A1-20040603-C00005.png)
JP2016506958A5 (US20040106767A1-20040603-C00005.png)
JP2011105738A5 (US20040106767A1-20040603-C00005.png)
JP2016505637A5 (US20040106767A1-20040603-C00005.png)
JP2013032389A5 (US20040106767A1-20040603-C00005.png)
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
JP2014525420A5 (US20040106767A1-20040603-C00005.png)
JP2017509586A5 (US20040106767A1-20040603-C00005.png)
JP2017511321A5 (US20040106767A1-20040603-C00005.png)
JP2016537382A5 (US20040106767A1-20040603-C00005.png)
JP2016507581A5 (US20040106767A1-20040603-C00005.png)
JP2018514522A5 (US20040106767A1-20040603-C00005.png)
JP2014510147A5 (US20040106767A1-20040603-C00005.png)
JP2013532130A5 (US20040106767A1-20040603-C00005.png)
WO2014192030A3 (en) An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof